Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/93149
Title: Mitochondrial and redox-based therapeutic strategies in Huntington's disease
Authors: Fão, Lígia 
Rego, Ana Cristina
Keywords: Huntington’s Disease, mitochondrial dysfunction, oxidative stress, mutant huntingtin, therapies
Issue Date: 4-Jun-2020
Serial title, monograph or event: Antioxid Redox Signal
Abstract: Significance: The molecular processes that determine Huntington's disease (HD) pathogenesis are not yet fully understood, and until now no effective neuroprotective therapeutic strategies have been developed. Mitochondria are one of most important organelles required for neuronal homeostasis, by providing metabolic pathways relevant for energy production, regulating calcium homeostasis, or controlling free radical generation and cell death. Because augmented reactive oxygen species (ROS) accompanied by mitochondrial dysfunction are relevant early HD mechanisms, targeting these cellular mechanisms may constitute relevant therapeutic approaches. Recent Advances: Previous findings point toward a close relationship between mitochondrial dysfunction and redox changes in HD. Mutant huntingtin (mHTT) can directly interact with mitochondrial proteins, as translocase of the inner membrane 23 (TIM23), disrupting mitochondrial proteostasis and favoring ROS production and HD progression. Furthermore, abnormal brain and muscle redox signaling contributes to altered proteostasis and motor impairment in HD, which can be improved with the mitochondria-targeted antioxidant mitoquinone or resveratrol, an SIRT1 activator that ameliorates mitochondrial biogenesis and function. Critical Issues: Various antioxidants and metabolic enhancers have been studied in HD; however, the real outcome of these molecules is still debatable. New compounds have proven to ameliorate mitochondrial and redox-based signaling pathways in early stages of HD, potentially precluding selective neurodegeneration. Future Directions: Unraveling the molecular etiology of deregulated mitochondrial function and dynamics, and oxidative stress opens new prospects for HD therapeutics. In this review, we explore the role of redox unbalance and mitochondrial dysfunction in HD progression, and further describe advances on clinical trials in HD based on mitochondrial and redox-based therapeutic strategies.
URI: http://hdl.handle.net/10316/93149
DOI: 10.1089/ars.2019.8004
Rights: openAccess
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
Revised_Fão & Rego_ARS_HD Mito.ther_(13-May-20)_vf(no figures)_ref update.docxAccepted Ms303.88 kBMicrosoft Word XMLView/Open
Show full item record

WEB OF SCIENCETM
Citations

2
checked on Jun 2, 2021

Page view(s)

27
checked on Jun 9, 2021

Download(s)

8
checked on Jun 9, 2021

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.